An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer

An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer

Treatment with the anti‐angiogenic drug bevacizumab in addition to chemotherapy has shown efficacy for breast cancer in some clinical trials, but better biomarkers are needed to optimally select patients for treatment. Here, we present an omics approach where DNA methylation profiles are integrated...

Full description

Bibliographic Details
Main Authors: Thomas Fleischer, Mads Haugland Haugen, Jørgen Ankill, Laxmi Silwal‐Pandit, Anne‐Lise Børresen‐Dale, Ingrid Hedenfalk, Thomas Hatschek, Jörg Tost, Olav Engebraaten, Vessela N. Kristensen
Format: Article
Language:English
Published: Wiley 2024-08-01
Series:Molecular Oncology
Subjects:
bevacizumab
breast cancer
chemotherapy
DNA methylation
epigenetics
multiomics
Online Access:https://doi.org/10.1002/1878-0261.13656

Internet

https://doi.org/10.1002/1878-0261.13656

Similar Items